Celltrion Decides on Additional Share Buyback Worth 100 Billion KRW

A Total of 450 Billion KRW in Share Buybacks This Year
All Acquired Shares to Be Retired

Celltrion announced on April 28 that its board of directors has decided to conduct an additional share buyback worth approximately 100 billion KRW. The number of shares to be repurchased amounts to 631,712. The buyback will be carried out through on-market purchases starting from April 29.

Celltrion

Since January of this year, the total value of Celltrion's share buybacks has reached approximately 450 billion KRW, already surpassing last year's total buyback amount of about 436 billion KRW. In addition, recently, Seo Jungjin, chairman of Celltrion Group, the holding company Celltrion Holdings, and the group affiliate Celltrion Skincure, each decided to acquire shares worth 50 billion KRW, 100 billion KRW, and 50 billion KRW, respectively. When combined, the total scale of Celltrion shares to be purchased on the market at the group level is expected to reach approximately 650 billion KRW.

Celltrion employees are also expected to actively acquire Celltrion shares through their employee stock ownership association, based on the company's future growth potential and inherent competitiveness. The employee stock ownership association is arranging loans for acquisition funds up to the maximum annual salary of each employee and is currently proceeding with the subscription process this month to purchase shares on the market.

Celltrion is not only actively buying back its own shares but is also aggressively retiring them, accelerating efforts to enhance shareholder value. The total value of treasury shares that Celltrion has either retired or decided to retire so far this year has already exceeded approximately 800 billion KRW. Furthermore, the company plans to fulfill its promise to shareholders to retire all treasury shares acquired this year.

Celltrion Group's aggressive share buybacks and treasury share retirements are considered among the highest in the industry. The company is also implementing a value-up program aimed at achieving an average shareholder return rate of 40% over the next three years.

The company stated that it will continue to actively implement additional shareholder-friendly policies to protect shareholder interests if the company's value remains undervalued due to ongoing internal and external market uncertainties.

Celltrion also plans to continue strengthening its product and market competitiveness in the global market. The company achieved its goal of building a portfolio of 11 biosimilars by 2025 ahead of schedule last year and is now accelerating efforts to obtain approval for 22 biosimilars by 2030. In particular, Celltrion plans to actively advance the development of 13 new drug candidates by 2028, including entering the global clinical stage for next-generation antibody-drug conjugate (ADC) therapies this year.

A Celltrion representative stated, "Believing that the company's value is undervalued, we are accelerating efforts to maximize shareholder value by conducting a relay of share buybacks and retirements," adding, "Despite recent domestic and international uncertainties, Celltrion remains confident in its growth potential and will do its utmost to expand performance and strengthen competitiveness."